Alexander S. Cheung
YOU?
Author Swipe
View article: 278 Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors
278 Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors Open
Background Effective solid tumor cell therapy requires new strategies to improve T-cell activation, persistence, and durable function.1 2 We developed four complementary, stackable T-cell reprogramming technologies to enhance chimeric anti…
View article: Biophysical induction of cell release for minimally manipulative cell enrichment strategies
Biophysical induction of cell release for minimally manipulative cell enrichment strategies Open
The use of autologous cells harvested and subsequently transplanted in an intraoperative environment constitutes a new approach to promote regeneration. Usually cells are isolated by selection methods such as fluorescence- or magnetic- act…
View article: Engineered Materials for Improving Cancer Immunotherapy
Engineered Materials for Improving Cancer Immunotherapy Open
Immunotherapy, the treatment of disease through targeted activation of the immune system, has recently shown unprecedented clinical success for diverse malignancies. In contrast to traditional cancer treatments, which are associated with w…
View article: Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy
Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy Open
Overcoming the immunosuppressive tumor microenvironment (TME) is critical to realizing the potential of cancer immunotherapy strategies. Agonists of stimulator of interferon genes (STING), a cytosolic immune adaptor protein, have been show…
View article: Adjuvant‐Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination
Adjuvant‐Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination Open
Targeted subunit vaccines for cancer immunotherapy do not capture tumor antigenic complexity, and approaches employing tumor lysate are often limited by inefficient antigen uptake and presentation, and low immunogenicity. Here, whole cance…